Latest Abbott Stories

ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis(®) ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with XALKORI (crizotinib), an oral...

ABBOTT PARK, Ill., Oct. 22, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA® (adalimumab) ULTRA 1 and ULTRA 2 studies. Adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to certain other medications and were treated with HUMIRA were evaluated for symptom improvement for up to three years. In this long-term...

WATERTOWN, Mass., Oct. 17, 2012 /PRNewswire/ -- Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced that Abbott initiated an interferon-free combination Phase 3 clinical trial for hepatitis C (HCV) that included the collaboration's protease inhibitor, ABT-450. This trial was initiated following the release of positive results from the study known as "Aviator",...

ABBOTT PARK, Ill., Oct. 17, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2012. Diluted earnings per share, excluding specified items, were $1.30, reflecting 10.2 percent growth, exceeding Abbott's guidance range. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $1.21, including specified items. Excluding foreign exchange, worldwide sales increased 4.1 percent. Reported...

ABBOTT PARK Ill., Oct. 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99 percent of treatment-naive (n=77) and 93 percent of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin...

ABBOTT PARK, Ill., Oct. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the winners of the CFCareForward Thriving Undergraduate and Graduate Scholarship award. Mark Moening, a Virginia Beach, Va. resident, and Wesley McSparin, a native of Paducah, Ky., were unveiled as the 2012 Thriving Undergraduate and Graduate Scholarship recipients, respectively. In celebration of the 20(th) anniversary of the program, the total award is $20,000. Earlier this year, 40...

ABBOTT PARK, Ill., Oct. 3, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2012 financial results on Wednesday, Oct. 17, 2012, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time. About...

ABBOTT PARK, Ill., Sept. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary...

ABBOTT PARK, Ill., Sept. 25, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that Absorb(TM), the world's first drug eluting bioresorbable vascular scaffold (BVS), is now widely available across Europe and parts of Asia Pacific and Latin America. Absorb is a first-of-its-kind device for the treatment of coronary artery disease (CAD). It works by restoring blood flow to the heart similar to a metallic stent, but then dissolves into the body, leaving behind a treated...

The Consumer Justice Foundation, a for-profit corporation whose team of professional consumer advocates whose mission is to provide the public with free information regarding the potential dangers of using certain prescription medications, has a Web site URL of http://www.depakotebirthinjury.com. The CJF hereby reports that the Attorney General of Mississippi has announced that his office has reached a settlement agreement in the amount of $840,000.00 with Abbott Laboratories for its...